Mirae Asset Global Investments
DSGN icon

Mirae Asset Global Investments’s Design Therapeutics DSGN Stock Holding History

Mirae Asset Global Investments’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.4K Sell
2,793
-178
-6% -$2.22K ﹤0.01% 1391
2026
Q1 		$31.6K Buy
2,971
+203
+7% +$2.05K ﹤0.01% 1373
2025
Q4 		$26K Buy
2,768
+566
+26% +$4.43K ﹤0.01% 1503
2025
Q3 		$16.6K Buy
2,202
+9
+0.4% +$45 ﹤0.01% 1514
2025
Q2 		$7.39K Buy
2,193
+298
+16% +$1.11K ﹤0.01% 1522
2025
Q1 		$7.98K Buy
1,895
+8
+0.4% +$38 ﹤0.01% 1490
2024
Q4 		$11.8K Buy
+1,887
New +$10.9K ﹤0.01% 1494
2024
Q2 		– Sell
-14,133
Closed -$77.7K – 1799
2024
Q1 		$77.7K Buy
+14,133
New +$37.7K ﹤0.01% 2397
2023
Q3 		– Sell
-15,398
Closed -$97K – 2590
2023
Q2 		$97K Sell
15,398
-114
-0.7% -$698 ﹤0.01% 2519
2023
Q1 		$89.5K Sell
15,512
-36
-0.2% -$269 ﹤0.01% 2462
2022
Q4 		$160K Buy
15,548
+22
+0.1% +$298 ﹤0.01% 2351
2022
Q3 		$259K Buy
+15,526
New +$309K ﹤0.01% 2226

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Logos Global Management
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Mirae Asset Global Investments's DSGN Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Design Therapeutics (DSGN) stake by 6% in Q2 2026, selling an estimated $2.22K and leaving 2,793 shares worth $40.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1391.

Mirae Asset Global Investments first reported a position in DSGN in Q3 2022 and has held it in 12 quarters since. The position peaked at $259K in Q3 2022. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Mirae Asset Global Investments held 2,793 shares of Design Therapeutics worth $40.4K as of Q2 2026.
  • Mirae Asset Global Investments sold 178 Design Therapeutics shares in Q2 2026, an estimated $2.22K.
  • Design Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1391 holding.
  • Mirae Asset Global Investments first reported a position in Design Therapeutics in Q3 2022 and has held it in 12 quarters since.
  • Mirae Asset Global Investments's Design Therapeutics position peaked at $259K in Q3 2022.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.